ATYR PHARMA, INC. (NASDAQ:LIFE) Files An 8-K Regulation FD Disclosure

ATYR PHARMA, INC. (NASDAQ:LIFE) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Story continues below

aTyr Pharma, Inc. (the “Company”) is participating at the 2018 American Association for Cancer Research (AACR) Annual Meeting held April 14-18, 2018 in Chicago, Illinois.During the AACR Annual Meeting, the Company is presenting two preclinical poster presentations for its immuno-oncology program based on the Resokine pathway.The poster presentations are entitled, “Circulating levels of Resokine, a soluble modulator of the immune system, are upregulated in both experimental cancer models and in patients across multiple tumor types,” and “Antibodies targeting Resokine, a soluble immune modulator, inhibit tumor growth in syngeneic mouse models.” The poster presentations have been posted on the Company’s website and are attached hereto as Exhibits 99.1 and 99.2.

The information under this Item 7.01, including Exhibits 99.1 and 99.2 hereto, are being furnished herewith and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Exhibits.


EX-99.1 2 life-ex991_61.htm EX-99.1 life-ex991_61.pptx.htm Normal Volunteers Solid Tumor Hematologic 1 10 100 1000 10000 Resokine (pM) 18% 2% ****,…
To view the full exhibit click here


aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

An ad to help with our costs